Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Lijun Says Enerxin Capsules Effective in Treating H1N1 Flu

publication date: Nov 10, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Lijun International Pharmaceutical (Holding) Co., Ltd. reported that its Enerxin Capsules, an antiviral drug, was recognized by the State Key Laboratory of Virology for effective restraint of the growth of influenza A (H1N1). The effects of the drug were similar to Tamiflu. Enerxin was developed by a subsidiary of Lijun, Shijiazhuang No.4 Pharmaceutical Co., Ltd. More details...

Stock Symbol: (HKEX: 2005)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



ChinaBio® Events
Partner Events

Shanghai, China
November 1-3, 2016

Shanghai, China
October 18-19, 2016

Del Mar, USA
October 1st, 2016

Del Mar, USA
October 1st, 2016

>> More events...